RT Journal Article
SR Electronic
T1 Effects of Last Dosing Time on Population Pharmacokinetic Analysis of Tacrolimus Performed using Extracted Data from Electronic Health Records
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.15.21249900
DO 10.1101/2021.01.15.21249900
A1 Michael L. Williams
A1 Hannah L. Weeks
A1 Cole Beck
A1 Leena Choi
YR 2021
UL http://medrxiv.org/content/early/2021/01/20/2021.01.15.21249900.abstract
AB A tacrolimus population pharmacokinetic (PK) study with 440 subjects was performed using real world data extracted from electronic heath records (EHRs) to identify patient factors affecting variability in tacrolimus PK parameters. Using last-dose times extracted by our own natural language processing system, medExtractR, we assessed the effects of incorporating last-dose times in the data on tacrolimus PK parameter estimates. The estimates of population level PK parameters were Cl = 24.9 L/h [23.5, 26.3] and V = 6310 L [5461, 7159]. There was no appreciable difference in parameters estimates with vs. without last-dose time incorporated in the data. We also investigated the effects of absorption rate constants that are often fixed at a published value in tacrolimus population PK analysis. Our sensitivity analysis revealed little difference between parameters estimated assuming a range of absorption rate constants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by NIH/NIGMS (R01-GM124109).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Vanderbilt Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not publicly available.